Customize your JAMA Network experience by selecting one or more topics from the list below.
In the Original Investigation titled “Pioglitazone Therapy in Patients With Stroke and Prediabetes: A Post Hoc Analysis of the IRIS Randomized Clinical Trial,”1 published online February 7, 2019, there was an error in the Discussion section. The second-to-last sentence before the Limitations section should read: “Myocardial infarction and stroke are very costly, so the balance of NNTs for beneficial outcomes and numbers needed to harm for adverse outcomes would suggest cost utility for pioglitazone, but we have not yet conducted a cost-utility calculation.” This article was corrected online.
Error in Discussion Section. JAMA Neurol. 2019;76(5):625–626. doi:10.1001/jamaneurol.2019.0475
Coronavirus Resource Center